Top

Published in:

01-08-2013 | Adis Drug Evaluation

Recombinant Trivalent Influenza Vaccine (Flublok^®): A Review of Its Use in the Prevention of Seasonal Influenza in Adults

Author: Lily P. H. Yang

Published in: Drugs | Issue 12/2013

Abstract

Flublok^® is a trivalent influenza vaccine manufactured using the baculovirus-insect cell system, which has a number of differences compared with the traditional embryonated chicken egg system. Flublok^® is the first vaccine containing recombinant protein to be approved for the prevention of seasonal influenza, and is indicated in the USA in adults aged 18–49 years. In a large, placebo-controlled, phase III trial in individuals aged 18–49 years, Flublok^® met the US FDA requirements for immunogenicity, effectiveness and safety, despite a high incidence of antigenic mismatch between confirmed cases of influenza and the vaccine component strains. Flublok^® was also compared with Fluzone^® in two noninferiority trials in older adults aged 50–64 or ≥65 years; although noninferiority was shown for a number of endpoints in these trials, Flublok^® is not currently approved in these age groups. Flublok^® is a useful and generally well-tolerated vaccination option for the prevention of seasonal influenza in adults aged 18–49 years, including those with egg allergy.

Fiore AE, Uyeki TM, Broder K, et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010 [published errata appear in MMWR Recomm Rep 2010;59(31):993 and 2010;59(35):1147]. MMWR Recomm Rep. 2010;59(RR-8):1–62.

Hogan TJ. Issues in the economic evaluation of influenza vaccination by injection of healthy working adults in the US: a review and decision analysis of ten published studies. Pharmacoeconomics. 2012;30(5):355–71.PubMedCrossRef

Newall AT, Kelly H, Harsley S, et al. Cost effectiveness of influenza vaccination in older adults: a critical review of economic evaluations for the 50- to 64-year age group. Pharmacoeconomics. 2009;27(6):439–50.PubMedCrossRef

de Waure C, Veneziano MA, Cadeddu C, et al. Economic value of influenza vaccination. Hum Vaccin Immunother. 2012;8(1):119–29.PubMedCrossRef

Rogers KC, Wallace JP, Foster SL, et al. Annual influenza vaccination: offering protection beyond infection. South Med J. 2012;105(7):379–86.PubMedCrossRef

Centers for Disease Control and Prevention (CDC). Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP)—United States, 2012–13 influenza season. MMWR Morb Mortal Wkly Rep. 2012;61(32):613–8.

Clements KM, Chancellor J, Nichol K, et al. Cost-effectiveness of a recommendation of universal mass vaccination for seasonal influenza in the United States. Value Health. 2011;14(6):800–11.

Mena JA, Kamen AA. Insect cell technology is a versatile and robust vaccine manufacturing platform. Expert Rev Vaccines. 2011;10(7):1063–81.PubMedCrossRef

Cox MM. Recombinant protein vaccines produced in insect cells. Vaccine. 2012;30(10):1759–66.PubMedCrossRef

10.

Protein Sciences Corporation. Flublok (influenza vaccine) sterile solution for intramuscular injection: US prescribing information; 12 Dec 2012. http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM336020.pdf (Accessed 27 Mar 2013).

11.

US FDA Centers for Disease Control and Prevention. CDC advisory committee recommends an influenza vaccine option for persons with egg allergy; 20 Jun 2013. http://www.cdc.gov/media/releases/2013/a0620-FluBlok.html (Accessed 1 Jul 2013).

12.

Cox MMJ, Hashimoto Y. A fast track influenza virus vaccine produced in insect cells. J Invertebr Pathol. 2011;107(Suppl):S31–41.PubMedCrossRef

13.

Post PL. Safety testing and use of insect cells for recombinant protein production. PDA J Pharm Sci Technol. 2010;64(5):396–418.PubMed

14.

Powers DC, Smith GE, Anderson EL, et al. Influenza A virus vaccines containing purified recombinant H3 hemagglutinin are well tolerated and induce protective immune responses in healthy adults. J Infect Dis. 1995;171(6):1595–9.PubMedCrossRef

15.

Treanor JJ, Betts RF, Smith GE, et al. Evaluation of a recombinant hemagglutinin expressed in insect cells as an influenza vaccine in young and elderly adults. J Infect Dis. 1996;173(6):1467–70.PubMedCrossRef

16.

Lakey DL, Treanor JJ, Betts RF, et al. Recombinant baculovirus influenza A hemagglutinin vaccines are well tolerated and immunogenic in healthy adults. J Infect Dis. 1996;174(4):838–41.PubMedCrossRef

17.

Powers DC, McElhaney JE, Florendo OA Jr, et al. Humoral and cellular immune responses following vaccination with purified recombinant hemagglutinin from influenza A (H3N2) virus. J Infect Dis. 1997;175(2):342–51.PubMedCrossRef

18.

Huber VC, McCullers JA. FluBlok, a recombinant influenza vaccine. Curr Opin Mol Ther. 2008;10(1):75–85.PubMed

19.

Treanor JJ, Schiff GM, Hayden FG, et al. Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: a randomized controlled trial. JAMA. 2007;297(14):1577–82.PubMedCrossRef

20.

Treanor JJ, Schiff GM, Couch RB, et al. Dose-related safety and immunogenicity of a trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine in elderly adults. J Infect Dis. 2006;193(9):1223–8.PubMedCrossRef

21.

Treanor JJ, El Sahly H, King J, et al. Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok) against influenza in healthy adults: a randomized, placebo-controlled trial. Vaccine. 2011;29(44):7733–9.PubMedCrossRef

22.

Baxter R, Patriarca PA, Ensor K, et al. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50–64 years of age. Vaccine. 2011;29(12):2272–8.PubMedCrossRef

23.

Keitel WA, Treanor JJ, El Sahly HM, et al. Comparative immunogenicity of recombinant influenza hemagglutinin (rHA) and trivalent inactivated vaccine (TIV) among persons ≥65 years old. Vaccine. 2009;28(2):379–85.PubMedCrossRef

24.

Smith NM, Bresee JS, Shay DK, et al. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP) [published erratum appears in MMWR MorbMortal Wkly Rep. 2006;55(29):800]. MMWR Recomm Rep. 2006;55(RR-10):1–42.

25.

Nolletti C, Schrager L. US FDA clinical review (Flublok); 15 Jan 2013. http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM341947.pdf (Accessed 28 Mar 2013).

26.

Fritz T. US FDA summary basis for regulatory action (Flublok); 16 Jun 2013. http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM338898.pdf (Accessed 28 Mar 2013).

27.

Novartis Vaccines and Diagnostics, Inc. Flucelvax (influenza virus vaccine) suspension for intramuscular injection: US prescribing information; 2012. http://www.novartisvaccinesdirect.com/pdf/Flucelvax_PI.pdf (Accessed 14 Jun 2013).

28.

European Medicines Agency. Questions and answers on the review of Preflucel and associated names (influenza vaccine, purified antigen); 19 Jul 2012. http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Preflucel/WC500130157.pdf (Accessed 30 Apr 2013).

29.

Cox MMJ, Hollister JR. FluBlok, a next generation influenza vaccine manufactured in insect cells. Biologicals. 2009;37(3):182–9.PubMedCrossRef

30.

Cox MMJ, Patriarca PA, Treanor J. FluBlok, a recombinant hemagglutinin influenza vaccine. Influenza Other Respi Viruses. 2008;2(6):211–9.PubMedCrossRef

31.

Wang K, Holtz KM, Anderson K, et al. Expression and purification of an influenza hemagglutinin: one step closer to a recombinant protein-based influenza vaccine. Vaccine. 2006;24(12):2176–85.PubMedCrossRef

32.

MedImmune, LLC. FluMist Quadrivalent (live influenza vaccine) intranasal spray: US prescribing information; Dec 2012. http://www.medimmune.com/docs/default-source/default-document-library/product-and-patient-information-for-flumist-quadrivalent.pdf?sfvrsn=0 (Accessed 14 Jun 2013).

33.

GlaxoSmithKline. Fluarix Quadrivalent (influenza virus vaccine) suspension for intramuscular injection: US prescribing information; Dec 2012. https://www.gsksource.com/gskprm/htdocs/documents/FLUARIX-QUADRIVALENT.PDF (Accessed 14 Jun 2013).

34.

Sanofi Pasteur Inc. Fluzone Quadrivalent (influenza virus vaccine) suspension for intramuscular injection: US prescribing information; Jun 2013. http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM356094.pdf (Accessed 1 Jul 2013).

35.

Sylte MJ, Suarez DL. Influenza neuraminidase as a vaccine antigen. Curr Top Microbiol Immunol. 2009;333:227–41.PubMedCrossRef

36.

Safdar A, Rodriguez MA, Fayad LE, et al. Dose-related safety and immunogenicity of baculovirus-expressed trivalent influenza vaccine: a double-blind, controlled trial in adult patients with non-Hodgkin B cell lymphoma. J Infect Dis. 2006;194(10):1394–7.PubMedCrossRef

37.

King JC Jr, Cox MM, Reisinger K, et al. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6–59 months. Vaccine. 2009;27(47):6589–94.PubMedCrossRef

38.

U. S. Department of Health and Human Services Food and Drug Administration Center for Bologics Evaluation and Research. Guidance for industry: clinical data needed to support the licensure of seasonal inactivated influenza vaccines; May 2007. http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm091990.pdf (Accessed 17 Apr 2013).

Title: Recombinant Trivalent Influenza Vaccine (Flublok®): A Review of Its Use in the Prevention of Seasonal Influenza in Adults
Author: Lily P. H. Yang
Publication date: 01-08-2013
Publisher: Springer International Publishing
Published in: Drugs / Issue 12/2013
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI: https://doi.org/10.1007/s40265-013-0103-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Recombinant Trivalent Influenza Vaccine (Flublok^®): A Review of Its Use in the Prevention of Seasonal Influenza in Adults

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 12/2013

Zonisamide: A Review of Its Use in the Management of Adults with Partial Seizures

Management of Neurogenic Orthostatic Hypotension in Patients with Autonomic Failure

Relapsed Triple-Negative Breast Cancer: Challenges and Treatment Strategies

Subcutaneous Immunoglobulin for Primary and Secondary Immunodeficiencies: an Evidence-Based Review

Extra-Esophageal Manifestations of Gastroesophageal Reflux Disease: Diagnosis and Treatment

Treatment of Opioid-Induced Constipation: Focus on the Peripheral μ-Opioid Receptor Antagonist Methylnaltrexone